<DOC>
	<DOC>NCT00170677</DOC>
	<brief_summary>Comparison of topotecan weekly vs. topotecan day 1-5. The compatibility and activity are to be examined.</brief_summary>
	<brief_title>Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer</brief_title>
	<detailed_description>Topotecan belongs to the most effective medicaments in the therapy of relapsed platin-resistant ovarian cancer. Due to the low rate of hematological toxicities of grade 3 or 4 weekly application may be an improvement of therapy. None randomised study exists comparing a weekly topotecan application with an application on day 1-5. This study will compare the two applications in regard to: rate of complete or partial remissions, rate of toxicity, quality of life, progression free survival, overall survival.</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>patients with histologicallyconfirmed ovarian cancer relapse within 6 month after primary therapy primary therapy with platin and taxan ECOG 02 &gt;= 18 years leukocytes &gt;= 3.000/ µl platelet &gt;= 100.000/ µl neutrophil &gt;= 1.500/ µl written informed consent earlier topotecan therapy simultaneous or planned radiotherapy secondary malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
</DOC>